MNA-001
/ Muna Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 10, 2025
Muna Therapeutics Announces First Subjects Dosed in Phase 1 Trial of Novel Oral TREM2 Agonist for Early Alzheimer’s Disease
(PRNewswire)
- "Phase 1 study initiated to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects of MNA-001 on biomarkers of TREM2 target engagement and activation, with topline data expected mid 2026."
P1 data • Trial status • Alzheimer's Disease
1 to 1
Of
1
Go to page
1